Evidence map›Paper›PMID 32432925›Full record

ArticleAmerican journal of physiology. Cell physiology2020

Extracellular adenosine enhances pulmonary artery vasa vasorum endothelial cell barrier function via Gi/ELMO1/Rac1/PKA-dependent signaling mechanisms.

Alexander D Verin, Robert Batori, Anita Kovacs-Kasa, Mary Cherian-Shaw, Sanjiv Kumar, Istvan Czikora, Vijaya Karoor, Derek Strassheim, Kurt R Stenmark, Evgenia V Gerasimovskaya

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alexander D VerinAugusta University Vascular Biology Center, Augusta, Georgia.
Robert BatoriAugusta University Vascular Biology Center, Augusta, Georgia.
Anita Kovacs-KasaAugusta University Vascular Biology Center, Augusta, Georgia.
Mary Cherian-ShawAugusta University Vascular Biology Center, Augusta, Georgia.
Sanjiv KumarAugusta University Vascular Biology Center, Augusta, Georgia.
Istvan CzikoraAugusta University Vascular Biology Center, Augusta, Georgia.
Vijaya KaroorDepartment of Medicine, University of Colorado Denver, Aurora, Colorado.
Derek StrassheimDepartment of Medicine, University of Colorado Denver, Aurora, Colorado.
Kurt R StenmarkDepartment of Pediatrics, University of Colorado Denver, Aurora, Colorado.
Evgenia V GerasimovskayaDepartment of Pediatrics, University of Colorado Denver, Aurora, Colorado.
Augusta University Health · USUniversity of Colorado Denver · US

Funding

Therapeutic Mechanisms of RhoA Inhibition In Acute Lung InjuryP01HL101902 · NHLBI · AUGUSTA UNIVERSITY · PI BLACK, STEPHEN M · 2011 to 2016
$11.2M
Extracellular ATP: potential regulator of hypoxia-induced vasa vasorum neovasculaR01HL086783 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI GERASIMOVSKAYA, EVGENIA V · 2008 to 2017
$4.2M
NHLBI NIH HHS HL101902NHLBI NIH HHS P01 HL101902NHLBI NIH HHS R01 HL086783
6 · The paper itself

Abstract

The vasa vasorum (VV), the microvascular network around large vessels, has been recognized as an important contributor to the pathological vascular remodeling in cardiovascular diseases. In bovine and rat models of hypoxic pulmonary hypertension (PH), we have previously shown that chronic hypoxia profoundly increased pulmonary artery (PA) VV permeability, associated with infiltration of inflammatory and progenitor cells in the arterial wall, perivascular inflammation, and structural vascular remodeling. Extracellular adenosine was shown to exhibit a barrier-protective effect on VV endothelial cells (VVEC) via cAMP-independent mechanisms, which involved adenosine A1 receptor-mediated activation of Gi-phosphoinositide 3-kinase-Akt pathway and actin cytoskeleton remodeling. Using VVEC isolated from the adventitia of calf PA, in this study we investigated in more detail the mechanisms linking Gi activation to downstream barrier protection pathways. Using a small-interference RNA (siRNA) technique and transendothelial electrical resistance assay, we found that the adaptor protein, engulfment and cell motility 1 (ELMO1), the tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2, and atypical Gi- and Rac1-mediated protein kinase A activation are implicated in VVEC barrier enhancement. In contrast, the actin-interacting GTP-binding protein, girdin, and the p21-activated kinase 1 downstream target, LIM kinase, are not involved in this response. In addition, adenosine-dependent cytoskeletal rearrangement involves activation of cofilin and inactivation of ezrin-radixin-moesin regulatory cytoskeletal proteins, consistent with a barrier-protective mechanism. Collectively, our data indicate that targeting adenosine receptors and downstream barrier-protective pathways in VVEC may have a potential translational significance in developing pharmacological approach for the VV barrier protection in PH.

Indexed as

Adaptor Proteins, Signal TransducingAdenosineAnimalsCattleCyclic AMP-Dependent Protein KinasesEndothelial CellsExtracellular FluidGTP-Binding Protein alpha Subunits, Gi-GoMalePulmonary Arteryrac1 GTP-Binding ProteinSignal TransductionVasa VasorumAdaptor Proteins, Signal TransducingAdenosineCyclic AMP-Dependent Protein KinasesELMO1 protein, mouseGTP-Binding Protein alpha Subunits, Gi-Gorac1 GTP-Binding Proteinadenosineendothelial barrierGiRac1vasa vasorum

Identifiers

PMID32432925
PMCPMC7468889
OpenAlexW3028348909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.